P38 mitogen-activated protein (MAP) kinase inhibitors - Pipeline Insight, 2024

This “P38 mitogen-activated protein (MAP) kinase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in P38 mitogen-activated protein (MAP) kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

P38 mitogen-activated protein (MAP) kinase inhibitors Understanding

P38 mitogen-activated protein (MAP) kinase inhibitors: Overview

A mitogen-activated protein kinase (MAPK or MAP kinase) is a type of protein kinase that is specific to the amino acids serine and threonine (i.e., a serine/threonine-specific protein kinase). MAPKs are involved in directing cellular responses to a diverse array of stimuli, such as mitogens, osmotic stress, heat shock and proinflammatory cytokines. They regulate cell functions including proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis. The p38 MAPKs are central regulators of the cellular response to inflammation, viral infection, and stress signals. The p38 MAPKs also plays roles in diverse biological processes such as cell proliferation, chemotaxis, tissue fibrosis, and vasculogenesis. Potent inhibitors of p38 MAPKs have been pursued as potential therapies for several disease indications due to their antiinflammatory properties, although none have been approved to date.

P38 mitogen-activated protein (MAP) kinase inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the P38 mitogen-activated protein (MAP) kinase inhibitors pipeline landscape is provided which includes the disease overview and P38 mitogen-activated protein (MAP) kinase inhibitors treatment guidelines. The assessment part of the report embraces, in depth P38 mitogen-activated protein (MAP) kinase inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, P38 mitogen-activated protein (MAP) kinase inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence P38 mitogen-activated protein (MAP) kinase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve P38 mitogen-activated protein (MAP) kinase inhibitors.

P38 mitogen-activated protein (MAP) kinase inhibitors Emerging Drugs Chapters

This segment of the P38 mitogen-activated protein (MAP) kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

P38 mitogen-activated protein (MAP) kinase inhibitors Emerging Drugs

ARRY-371797: Pfizer PF 07265803 is an orally active, small molecule, non-opioid analgesic that inhibits P38 mitogen-activated protein (MAP) kinase inhibitors, being developed by Pfizer for treatment of dilated cardiomyopathy due to a Lamin A/C gene mutation. It is being evaluated in Phase III stage of development for the treatment of dilatedcardiomyopathy.

Losmapimod: Fulcrum therapeutics/ Glaxo SmithKlineLosmapimod is a selective p38a/ß mitogen activated protein kinase (MAPK) inhibitor that was exclusively in-licensed from GSK by Fulcrum Therapeutics following Fulcrum’s discovery of the role of p38a/ß inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Utilizing its proprietary product engine, FulcrumSeek™, Fulcrum discovered that inhibition of p38a/ß reduced expression of the DUX4 gene in muscle cells derived from patients with FSHD. Although losmapimod has never previously been explored in muscular dystrophies, it has been evaluated in more than 3,600 subjects in clinical trials across multiple other indications, including in several Phase 2 trials and a Phase 3 trial. No safety signals were attributed to losmapimod in any of these trials. Losmapimod has been granted U.S. Food and Drug Administration (FDA) Fast Track designation and Orphan Drug Designation for the treatment ofFSHD.

P38 mitogen-activated protein (MAP) kinase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different P38 mitogen-activated protein (MAP) kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in P38 mitogen-activated protein (MAP) kinase inhibitors

There are approx. 8+ key companies which are developing the therapies for P38 mitogen-activated protein (MAP) kinase inhibitors. The companies which have their P38 mitogen-activated protein (MAP) kinase inhibitors drug candidates in the most advanced stage, i.e. phase III include Pfizer.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

P38 mitogen-activated protein (MAP) kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

P38 mitogen-activated protein (MAP) kinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses P38 mitogen-activated protein (MAP) kinase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging P38 mitogen-activated protein (MAP) kinase inhibitors drugs.

P38 mitogen-activated protein (MAP) kinase inhibitors Report Insights

• P38 mitogen-activated protein (MAP) kinase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

P38 mitogen-activated protein (MAP) kinase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing P38 mitogen-activated protein (MAP) kinase inhibitors drugs?
• How many P38 mitogen-activated protein (MAP) kinase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of P38 mitogen-activated protein (MAP) kinase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the P38 mitogen-activated protein (MAP) kinase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for P38 mitogen-activated protein (MAP) kinase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 1-3 business days.